Doxorubicin Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100960

CAS#: 23214-92-8 (free base)

Description: Doxorubicin free base, also called doxorubicin, is an anthracycline antibiotic with antineoplastic activity. Approved API for cancer therapeutic use is doxorubicin HCl. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Note: Doxorubicin free base has low solubility in common solvents. The MedKoo original CAT# for this product was 100280a.

Chemical Structure

Doxorubicin Free Base
CAS# 23214-92-8 (free base)

Theoretical Analysis

MedKoo Cat#: 100960
Name: Doxorubicin Free Base
CAS#: 23214-92-8 (free base)
Chemical Formula: C27H29NO11
Exact Mass: 543.17406
Molecular Weight: 543.52
Elemental Analysis: C, 59.66; H, 5.38; N, 2.58; O, 32.38.

Price and Availability

Size Price Availability Quantity
100.0mg USD 150.0 Same day
200.0mg USD 250.0 Same day
500.0mg USD 450.0 Same day
1.0g USD 750.0 Same day
2.0g USD 1250.0 Same day
5.0g USD 2650.0 Same day
Bulk inquiry

Related CAS #: 23214-92-8 (free base)   25316-40-9 (HCl)    

Synonym: ADR; chloridrato de doxorrubicina. Adriamycin; Adriacin; Adriblastina; Adriblastine; Adrimedac; DOXOCELL; Doxolem; Doxorubin; Farmiblastina; Rubex. Abbreviations: ADM; Adria; DOX. Code name: FI106;

IUPAC/Chemical Name: (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione.


InChi Code: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1

SMILES Code: O=C1C2=C(O)C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=O

Appearance: Deep-red to black solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: This product has low solubility in all common solvents.

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO at low concentration.

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 543.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Zhong YJ, Shao LH, Li Y. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 2013 Feb;42(2):373-83. doi: 10.3892/ijo.2012.1754. Epub 2012 Dec 28. Review. PubMed PMID: 23291656; PubMed Central PMCID: PMC3583876.

2: Xi L, Zhu SG, Das A, Chen Q, Durrant D, Hobbs DC, Lesnefsky EJ, Kukreja RC. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide. 2012 May 15;26(4):274-84. doi: 10.1016/j.niox.2012.03.006. Epub 2012 Apr 5. Review. PubMed PMID: 22484629; PubMed Central PMCID: PMC3360792.

3: Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21. Review. PubMed PMID: 22465037.

4: Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, Ruíz MA, Gallardo V, Aranega A. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70. Review. PubMed PMID: 22339066.

5: Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review. PubMed PMID: 22322832.

6: Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Review. PubMed PMID: 22260846.

7: Rakowski JA, Ahmad S, Holloway RW. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev Anticancer Ther. 2012 Jan;12(1):31-40. doi: 10.1586/era.11.187. Review. PubMed PMID: 22149430.

8: Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs. 2011 Dec 24;71(18):2531-58. doi: 10.2165/11207510-000000000-00000. Review. PubMed PMID: 22141391.

9: Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials. 2012 Feb;33(6):1689-98. doi: 10.1016/j.biomaterials.2011.11.004. Epub 2011 Dec 2. Review. PubMed PMID: 22137127.

10: Maeda M, Mabuchi S, Matsumoto Y, Hisamatsu T, Ohashi H, Kimura T. Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature. Eur J Gynaecol Oncol. 2011;32(5):542-6. Review. PubMed PMID: 22053671.

Additional Information

The original CAT# for this product was 100280a.